sample_id	singscore_F	singscore_M	ssgsea_F	ssgsea_M	delta_singscore	delta_ssgsea	title	status	submission_date	last_update_date	type	channel_count	source_name_ch1	organism_ch1	characteristics_ch1	characteristics_ch1.1	characteristics_ch1.2	characteristics_ch1.3	characteristics_ch1.4	characteristics_ch1.5	treatment_protocol_ch1	growth_protocol_ch1	molecule_ch1	extract_protocol_ch1	label_ch1	label_protocol_ch1	taxid_ch1	hyb_protocol	scan_protocol	data_processing	platform_id	contact_name	contact_email	contact_institute	contact_address	contact_city	contact_zip/postal_code	contact_country	supplementary_file	data_row_count	diagnosis:ch1	er-by-gene:ch1	her2-by-gene:ch1	origin:ch1	paired sample:ch1	tissue:ch1	group	pair_id
GSM3587381	4.679627515168413	13.82659245789621	NA	NA	0.6792571144402918	0	EA1690_01: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2positive	paired sample: 1	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587381/suppl/GSM3587381_EA1690_01.CEL.gz	22277	breast cancer	ERnegative	HER2positive	primary	1	primary breast cancer	primary	1
GSM3587382	4.339234391908033	10.67510754047034	NA	NA	1.1564320085277713	0	EA1690_02: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERpositive	her2-by-gene: HER2negative	paired sample: 2	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587382/suppl/GSM3587382_EA1690_02.CEL.gz	22277	breast cancer	ERpositive	HER2negative	primary	2	primary breast cancer	primary	2
GSM3587383	4.009413132665023	13.546578257535261	NA	NA	0.19269492385734488	0	EA1690_03: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERpositive	her2-by-gene: HER2negative	paired sample: 3	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587383/suppl/GSM3587383_EA1690_03.CEL.gz	22277	breast cancer	ERpositive	HER2negative	primary	3	primary breast cancer	primary	3
GSM3587384	3.87700489508338	13.64961572211945	NA	NA	0.05845456736009841	0	EA1690_04: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2positive	paired sample: 4	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587384/suppl/GSM3587384_EA1690_04.CEL.gz	22277	breast cancer	ERnegative	HER2positive	primary	4	primary breast cancer	primary	4
GSM3587385	4.873315522054533	14.3440355080032	NA	NA	0.7148056764376465	0	EA1690_05: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 5	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587385/suppl/GSM3587385_EA1690_05.CEL.gz	22277	breast cancer	ERnegative	HER2negative	primary	5	primary breast cancer	primary	5
GSM3587386	5.688753227474347	22.51829088933757	NA	NA	-0.5786444826622448	0	EA1690_06: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 6	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587386/suppl/GSM3587386_EA1690_06.CEL.gz	22277	breast cancer	ERnegative	HER2negative	primary	6	primary breast cancer	primary	6
GSM3587387	3.5086418884069768	14.362149014177369	NA	NA	-0.4175095466984431	0	EA1690_07: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 7	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587387/suppl/GSM3587387_EA1690_07.CEL.gz	22277	breast cancer	ERnegative	HER2negative	primary	7	primary breast cancer	primary	7
GSM3587388	3.117194935606317	5.725408756955617	NA	NA	1.3376996855873944	0	EA1690_08: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2positive	paired sample: 8	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587388/suppl/GSM3587388_EA1690_08.CEL.gz	22277	breast cancer	ERnegative	HER2positive	primary	8	primary breast cancer	primary	8
GSM3587389	5.240550506311586	18.36038402478796	NA	NA	0.05165477536200447	0	EA1690_09: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 9	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587389/suppl/GSM3587389_EA1690_09.CEL.gz	22277	breast cancer	ERnegative	HER2negative	primary	9	primary breast cancer	primary	9
GSM3587390	4.340379988680874	16.28235602470908	NA	NA	-0.19221563686502313	0	EA1690_10: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2positive	paired sample: 10	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587390/suppl/GSM3587390_EA1690_10.CEL.gz	22277	breast cancer	ERnegative	HER2positive	primary	10	primary breast cancer	primary	10
GSM3587391	4.158304468089673	12.717128041758231	NA	NA	0.5153976549674186	0	EA1690_11: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 11	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587391/suppl/GSM3587391_EA1690_11.CEL.gz	22277	breast cancer	ERnegative	HER2negative	primary	11	primary breast cancer	primary	11
GSM3587392	5.135460828388897	17.92667209472566	NA	NA	0.06918312572113039	0	EA1690_12: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 12	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587392/suppl/GSM3587392_EA1690_12.CEL.gz	22277	breast cancer	ERnegative	HER2negative	primary	12	primary breast cancer	primary	12
GSM3587393	3.98254519837429	15.99621884349714	NA	NA	-0.4191102902060971	0	EA1690_13: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERpositive	her2-by-gene: HER2negative	paired sample: 13	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587393/suppl/GSM3587393_EA1690_13.CEL.gz	22277	breast cancer	ERpositive	HER2negative	primary	13	primary breast cancer	primary	13
GSM3587394	6.262850946987204	20.351791670681358	NA	NA	0.41731872668489767	0	EA1690_14: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERpositive	her2-by-gene: HER2negative	paired sample: 14	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587394/suppl/GSM3587394_EA1690_14.CEL.gz	22277	breast cancer	ERpositive	HER2negative	primary	14	primary breast cancer	primary	14
GSM3587395	3.1971495133137866	13.80019444497579	NA	NA	-0.5397146089039759	0	EA1690_15: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERpositive	her2-by-gene: HER2negative	paired sample: 15	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587395/suppl/GSM3587395_EA1690_15.CEL.gz	22277	breast cancer	ERpositive	HER2negative	primary	15	primary breast cancer	primary	15
GSM3587396	5.211491529733617	18.63725491082661	NA	NA	-0.03900294920017722	0	EA1690_16: primary breast cancer	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	primary breast cancer	Homo sapiens	diagnosis: breast cancer	tissue: primary breast cancer	origin: primary	er-by-gene: ERnegative	her2-by-gene: HER2positive	paired sample: 16	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587396/suppl/GSM3587396_EA1690_16.CEL.gz	22277	breast cancer	ERnegative	HER2positive	primary	16	primary breast cancer	primary	16
GSM3587397	5.26947954873636	14.72535889427871	NA	NA	0.9504707976668642	0	EA1690_17: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2positive	paired sample: 1	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587397/suppl/GSM3587397_EA1690_17.CEL.gz	22277	breast cancer	ERnegative	HER2positive	brain	1	brain metastases	met	1
GSM3587398	2.8861102912158465	14.34381249095292	NA	NA	-0.9276426128931649	0	EA1690_18: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERpositive	her2-by-gene: HER2negative	paired sample: 2	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587398/suppl/GSM3587398_EA1690_18.CEL.gz	22277	breast cancer	ERpositive	HER2negative	brain	2	brain metastases	met	2
GSM3587399	2.88042743774078	15.453631434779489	NA	NA	-1.19945923945359	0	EA1690_19: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERpositive	her2-by-gene: HER2negative	paired sample: 3	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587399/suppl/GSM3587399_EA1690_19.CEL.gz	22277	breast cancer	ERpositive	HER2negative	brain	3	brain metastases	met	3
GSM3587400	4.500319878278793	14.446627218395701	NA	NA	0.38181781287493405	0	EA1690_20: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERpositive	her2-by-gene: HER2positive	paired sample: 4	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587400/suppl/GSM3587400_EA1690_20.CEL.gz	22277	breast cancer	ERpositive	HER2positive	brain	4	brain metastases	met	4
GSM3587401	3.521271628341027	8.89657280791862	NA	NA	0.9084252031344459	0	EA1690_21: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 5	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587401/suppl/GSM3587401_EA1690_21.CEL.gz	22277	breast cancer	ERnegative	HER2negative	brain	5	brain metastases	met	5
GSM3587402	2.974783201649	17.539155677029818	NA	NA	-1.6234301329783534	0	EA1690_22: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 6	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587402/suppl/GSM3587402_EA1690_22.CEL.gz	22277	breast cancer	ERnegative	HER2negative	brain	6	brain metastases	met	6
GSM3587403	4.25811173666008	12.57339856764906	NA	NA	0.6324861072859349	0	EA1690_23: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2positive	paired sample: 7	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587403/suppl/GSM3587403_EA1690_23.CEL.gz	22277	breast cancer	ERnegative	HER2positive	brain	7	brain metastases	met	7
GSM3587404	3.778649483864837	12.95000981932548	NA	NA	0.14554640065674573	0	EA1690_24: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 8	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587404/suppl/GSM3587404_EA1690_24.CEL.gz	22277	breast cancer	ERnegative	HER2negative	brain	8	brain metastases	met	8
GSM3587405	8.930956147165437	24.18902217263355	NA	NA	1.6990374958569827	0	EA1690_25: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 9	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587405/suppl/GSM3587405_EA1690_25.CEL.gz	22277	breast cancer	ERnegative	HER2negative	brain	9	brain metastases	met	9
GSM3587406	3.8800096510983897	15.17108874164358	NA	NA	-0.3052613974489339	0	EA1690_26: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2positive	paired sample: 10	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587406/suppl/GSM3587406_EA1690_26.CEL.gz	22277	breast cancer	ERnegative	HER2positive	brain	10	brain metastases	met	10
GSM3587407	4.898731766787987	19.604600421574162	NA	NA	-0.5303389437958395	0	EA1690_27: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 11	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587407/suppl/GSM3587407_EA1690_27.CEL.gz	22277	breast cancer	ERnegative	HER2negative	brain	11	brain metastases	met	11
GSM3587408	5.412343630882416	19.86070701926959	NA	NA	-0.16746052964247782	0	EA1690_28: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 12	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587408/suppl/GSM3587408_EA1690_28.CEL.gz	22277	breast cancer	ERnegative	HER2negative	brain	12	brain metastases	met	12
GSM3587409	3.50712286408993	14.615195213031761	NA	NA	-0.4796701317748329	0	EA1690_29: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2negative	paired sample: 13	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587409/suppl/GSM3587409_EA1690_29.CEL.gz	22277	breast cancer	ERnegative	HER2negative	brain	13	brain metastases	met	13
GSM3587410	5.10835940255979	20.88168954980492	NA	NA	-0.6644529648299239	0	EA1690_30: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERpositive	her2-by-gene: HER2negative	paired sample: 14	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587410/suppl/GSM3587410_EA1690_30.CEL.gz	22277	breast cancer	ERpositive	HER2negative	brain	14	brain metastases	met	14
GSM3587411	5.257339944606094	24.93428503743988	NA	NA	-1.5167237942855638	0	EA1690_31: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERpositive	her2-by-gene: HER2negative	paired sample: 15	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587411/suppl/GSM3587411_EA1690_31.CEL.gz	22277	breast cancer	ERpositive	HER2negative	brain	15	brain metastases	met	15
GSM3587412	3.47356684218604	13.79520796632714	NA	NA	-0.31004481478326573	0	EA1690_32: brain metastases	Public on Sep 25 2019	Feb 01 2019	Sep 25 2019	RNA	1	brain metastases	Homo sapiens	diagnosis: breast cancer	tissue: brain metastases	origin: brain	er-by-gene: ERnegative	her2-by-gene: HER2positive	paired sample: 16	Two of 16 patients were found to have brain metastases when first diagnosed with breast cancer; the remaining patients were diagnosed with brain metastases subsequent to treatment for early or advanced breast cancer.	Sixteen paired matched samples from primary breast cancers and brain metastases diagnosed between April 1, 2001 and December 31, 2012 were collected from 8 institutions.	total RNA	Matching primary breast cancers and brain metastases Formalin-Fixed Paraffin-Embedded (FFPE) specimens for gene expression analysis were collected into RNA. RNA from specimens was isolated, and quantity and quality of the each RNA was using an Agilent 2100 Bioanalyzer (Agilent Technologies).	biotin	Not provided.	9606	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	Genome-wide expression levels of transcripts were analyzed using the Affymetrix U133A gene chips (Affymetrix) according to the manufacture’s instructions.	All gene expression data were normalized with the MAS5 algorithm (http://www.bioconductor.org) with the mean expression centered to 600 and log 2 transformed.	GPL571	TAKAYUKI,,IWAMOTO	tiwamoto@cc.okayama-u.ac.jp	Okayama university hospital	2-5-1 Shikata-cho, Kitaku	Okayama	700-8558	Japan	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3587nnn/GSM3587412/suppl/GSM3587412_EA1690_32.CEL.gz	22277	breast cancer	ERnegative	HER2positive	brain	16	brain metastases	met	16
